ClinicalTrials.gg
CompletedNCT03898583Updated Feb 24, 2025

Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.

A Phase 1 interventional study of Microarray patch A and Microarray patch B in Psoriasis Vulgaris, sponsored by LEO Pharma. Completed at 2 sites in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by LEO Pharma · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.

Enrollment
41st of 47
15 · median 200
Started
2019
with 1 other
Phase 1
5 of 47
none open now
Registered
38th of 47
by date
Lead sponsor
22 of 47
LEO Pharma

Among the 47 studies testing calcipotriene in Psoriasis, this one is the 41st largest by enrollment, is one of 2 that started in 2019, is one of 5 in phase 1, and was the 38th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About calcipotriene

calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing calcipotriene in Psoriasis, or all of them as a file.
02

Study summary

To assess safety, tolerability and pharmacodynamics effect of treatment with microarray patches containing calcipotriol and betamethasone dipropionate.

03

Conditions studied

  • Psoriasis Vulgaris

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Subjects with psoriasis vulgaris in a chronic stable phase and mild to moderate plaque(s) covering a sufficient area to allocate 4 test fields on up to 3 comparable plaques.
  • Men and women aged 18-70 years (inclusive).
  • Sufficient target lesion(s) must be present on the trunk or extremities (excluding palms/soles); psoriatic lesions on the knees or elbows are not to be used as target lesions.
  • Plaques to be treated should have a comparable thickness of the EPB of the inflammatory infiltrate of at least 200 μm.
  • Plaques to be treated should have no more than a 2-fold difference in infiltrate thickness between the test fields.
  • Physical examination of skin must be without abnormal, clinical significant findings other than psoriasis vulgaris unless the investigator considers an abnormality to be irrelevant to the trial outcome.

Key Exclusion Criteria:

  • Other skin disease noted on physical examination that is considered by the investigator to be relevant to the outcome of the trial.
  • Subjects with acute psoriasis guttata, psoriasis punctata, psoriasis erythrodermatica, pustular, exfoliative or inverse psoriasis.
  • History of psoriasis that was unresponsive or poorly responsive to topical treatments.
  • Topical antipsoriatics are not permitted on the same body area as plaques to be treated during the 4 weeks before first treatment and during the trial.
  • Systemic treatment with antipsoriatics e.g. , cytostatics, retinoids, dimethylfumarate, apremilast in the 3 months before first treatment and during the trial.
  • Systemic treatment with biological treatments: rituximab within 12 months, ustekinumab or secukinumab within 6 months before first treatment and during the trial.
  • Systemic treatment with biological treatments within 3 months before first treatment and during the trial.
  • Systemic treatment with any other biological treatments within the period of 5 half-lives of the biological before first treatment and during the trial.
  • UV-therapy or extensive exposure to UV radiation or sunlight within 4 weeks before first treatment and during the trial.
  • Treatment with concomitant medication that may affect and provoke or aggravate psoriasis, unless on a stable dose for 3 months before trial medication initiation.
  • Any other topical medication on the plaques to be treated during the trial.
  • abnormal vital signs (blood pressure, and pulse) at screening (V1).
  • History/symptoms of a clinically significant illness before first treatment (past 5 years) and during the trial that in the investigator's opinion may place the subject at risk.
  • History/symptoms of a clinically significant illness before first treatment (past 5 years) and during the trial that in the investigator's opinion may influence the trial outcome.
  • Other clinically significant abnormal laboratory results.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Microarray patch A

    21 day treatment, once weekly, 3 applications in total, transdermal patch for cutaneous use

    Drug: Microarray patch A

  • Experimental
    Microarray patch B

    21 day treatment, 3 times weekly, 9 applications in total, transdermal patch for cutaneous use

    Drug: Microarray patch B

  • Placebo comparator
    Vehicle

    21 day treatment, once weekly, 3 applications in total, transdermal patch for cutaneous use, no active substance

    Drug: Placebo

  • Active comparator
    Daivobet

    21 day treatment, paused on day 7, day 14 and day 21, Cutaneous use

    Drug: Daivobet

Interventions

  • Microarray patch

    Also known as: Calcipotriol, Betamethasone dipropionate

  • Microarray patch

    Also known as: Calcipotriol, Betamethasone dipropionate

  • DrugPlacebo

    Microarray patch vehicle

  • DrugDaivobet

    Daivobet Gel

    Also known as: Calcipotriol, Betamethasone dipropionate

06

What researchers measure

Primary outcomes

  1. Overall number of treatment-emergent adverse events.

    Time frame: First IMP application up to trial end (Day 50)

  2. Number of treatment-emergent application site reactions, by treatment

    Time frame: First IMP application up to trial end (Day 50)

  3. Change from baseline to Day 22 (EoT) in haematology parameters.

    RBC, WBC, haemoglobin, haematocrit, platelets, white cell differentials; measured in SI units.

    Time frame: From baseline up to EoT (Day 22)

  4. Change from baseline to Day 22 (EoT) in clinical chemistry parameters.

    Sodium, potassium, BUN, glucose, AST, ALT, gamma GT, AP, calcium, phosphate, albumin, total cholesterol, LDH, total protein, creatinine, total bilirubin; measured in SI units.

    Time frame: From baseline to EoT (Day 22)

  5. Change from baseline to Day 22 (EoT) in urinalysis parameters, single parameters only to be listed if deviation from usual urine dip test.

    E.g., leukocytes, nitrite, pH, protein, glucose, ketones, urobilinogen, bilirubin, blood/haemoglobin, measured in SI units.

    Time frame: From baseline to EoT (Day 22)

  6. Number of subjects with abnormal clinically significant findings of physical examination at Day 22 (EoT).

    Evaluation of physical examination (areas skin, heart, lung, abdomen, basic neurological status, general examination of eyes, ears, nose, throat), overall evaluation, assessed by investigator as 'normal', 'abnormal not clinically significant', 'abnormal clinically significant'.

    Time frame: EoT (Day 22)

  7. Change from baseline to Day 22 (EoT) in systolic and diastolic blood pressure.

    Measured in mmHg.

    Time frame: From baseline to EoT (Day 22)

  8. Change from baseline to Day 22 (EoT) in pulse.

    Measured in beats per minute.

    Time frame: From baseline to EoT (Day 22)

  9. Frequency counts of overall tolerability assessment of skin reactions at Day 8, Day 15, Day 22, Day 36 and Day 50.

    (Assessment performed by an investigator using a 4-point score \['0 = very good', '1 = good', '2 = moderate', '3 = poor'\]).

    Time frame: From baseline up to trial end (Day 50)

Secondary outcomes

  1. Change from baseline (pre-dose at Day 1) to Day 22 (EoT) in psoriatic infiltrate thickness.

    (Assessed by measurement of the thickness of the Echo Poor Band \[EPB\] of the inflammatory infiltrate using 22-MHz sonography; measured in µm).

    Time frame: EoT (Day 22)

07

Study locations

2 sites
  • LEO Pharma investigational site
    Berlin, 10783, Germany
  • LEO Pharma investigational site
    Hamburg, 20098, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Oct 2019, 6 months.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 6 months is below that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2019
First posted
Apr 2, 2019
StartActual
Apr 15, 2019
Primary completionActual
Oct 29, 2019
CompletionActual
Oct 29, 2019
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03898583
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Apr 2, 2019
Start date
Apr 15, 2019
Primary completion
Oct 29, 2019
Completion
Oct 29, 2019
Last update
Feb 24, 2025

Study contacts

Medical Expert
study director · LEO Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Calcipotriene

Start the discussion